Professional Excellence, Mission Delivered: MDCE CRO Earns International Client Acclaim for Enabling Chinese Innovation Globalization

In November 2025, a China-headquartered multinational cardiovascular interventional company specifically addressed the rapid progress of its international multicenter clinical study for its core product to a China-headquartered multinational CRO-Thank-You Letter from MDCE CRO (Xiyi Medicine), for its project atEurope, Middle EastThe significant interim achievements attained have been highly recognized. This progress not only marks a further enhancement of the company’s global scientific leadership, but also demonstrates that it has taken a comprehensive lead in global innovation within relevant fields, fully showcasing the robust capabilities of leading Chinese enterprises in international regulatory approvals, clinical trials, and commercialization. This letter of commendation serves as further affirmation of Xi Yi Medicine’s professional expertise, and even more so, of its continued commitment to providing customers withReliable, Efficient, End-to-End, and Affordable One-Stop Solution for International Clinical ResearchA Strong Demonstration of Professional Competence.

In global multi-center clinical trials, coordinated operations across regions, regulations, currencies, and cultures represent a core challenge. Leveraging its deeply established overseas local teams and integrated project delivery system, Xi Yi Medicine demonstrated exceptional end-to-end execution capabilities in this project:

• In the UK, as the first country to obtain regulatory approval for the project, successfully established a research foundation meeting high international standards, setting a compliance benchmark for subsequent global clinical development;

• In Germany, the team efficiently obtained full regulatory approval and rapidly completed site initiation and activation (SIV), laying the foundation for accelerated patient enrollment;

•In Qatar, in the face of practical challenges associated with cross-border payments and local currency settlement, XiYi Medical’s finance and project management teams responded with agility, ensuring timely payment of investigator fees and facilitating the subsequent smooth activation of the research sites.

These breakthroughs at key milestones demonstrate Xi Yi Medicine’sCross-Border Regulatory Submissions, Rapid Site Activation, and Compliant Cross-Border Fund Managementsystematic professional capabilities across key stages ensure the efficient and smooth advancement of client projects on the international stage.

The clinical milestones achieved by the client in Europe and the Middle East represent not only progress in a single project, but also a significant marker of Chinese innovative medical device enterprises actively integrating into the global R&D ecosystem and targeting commercialization in international markets. Xiyi Medicine deeply understands the needs and challenges of Chinese companies expanding overseas, and is committed to providingOne-stop clinical research solutions, from upfront strategic consulting, country and site selection, end-to-end operational management, to regulatory registration support,By establishing a localized service network covering key markets in Europe and the United States, the Middle East, and the Asia-Pacific region, and by building an efficient and transparent cross-border collaboration platform, we help clients significantly shorten global clinical development cycles and reduce compliance and operational risks. This enables them to bring globally competitive innovative products to market more rapidly, thereby maximizing commercial value.

The client specifically praised the Xi Yi Medical team for their “strong operational capabilities and collaborative spirit” in the letter, and acknowledged their “significant contribution to shared goals.”. This aligns perfectly with Xi Yi Medicine“Customer First, Value Co-creation”collaborative philosophy. We not only consistently adhere to the professional principles of scientific rigor, compliance, efficiency, and transparency in serving our clients, but also act as their strategic partners on the path to global clinical development, working hand in hand with them to overcome challenges and achieve key milestones together.

This formal recognition by internationally leading clients serves as strong testament to XiYi Medical’s professional expertise and the quality of its project delivery. Moving forward, we will continue to enhance our global service capabilities and refine operational excellence, empowering more Chinese biopharmaceutical and medical device companies to navigate complex international clinical environments and expand globally with confidence, thereby ensuring that medical innovations originating in China benefit patients worldwide at an earlier stage.

Xiyi Medical is a medical device R&D outsourcing company centered on global clinical trials. Leveraging Harvard University’s global medical research resources and academic influence, the company has established a comprehensive overseas service value chain to provide customized market-entry solutions for Chinese medical device enterprises. Its services encompass overseas clinical development strategy and design, management and operations of overseas clinical trials, overseas product registration, and international commercialization planning. Since its inception, Xiyi Medical has successfully facilitated the overseas launch of more than 80 medical device and biopharmaceutical projects, generating cumulative overseas profits exceeding RMB 20 billion for its clients. Currently, Xiyi Medical employs an in-house overseas clinical trial team of over 100 professionals, collaborates with more than 2,000 experts, and has partnered with over 100 renowned overseas hospitals, covering regions including the European Union, North America, Australia and New Zealand, Southeast Asia, Japan and South Korea, the Middle East, and Africa.

For inquiries regarding overseas clinical trials and regulatory affairs, please scan the QR code to submit your information or contact us via the following methods:

Phone: +86 18611648819

Email: ask@mdcecro.com